# Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

> **NCT03299049** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 1049 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Cabotegravir Tablets
- **DRUG:** Rilpivirine Tablets
- **DRUG:** Cabotegravir Injectable Suspension
- **DRUG:** Rilpivirine Injectable Suspension

## Key facts

- **NCT ID:** NCT03299049
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-27
- **Primary completion:** 2019-06-06
- **Final completion:** 2029-12-31
- **Target enrollment:** 1049 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03299049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03299049, "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03299049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*